Radical surgery for gastric carcinoma: It is not an issue of whether to perform D1 or D2. Dissect as many lymph nodes as possible and you will be rewarded

Acta Chirurgica Belgica

Volumn 109, Issue 1, 2009, Pages 27-35

  Kodera, Y ^a   Fujiwara, M ^a   Ito, Y ^a   Ohashi, N ^a   Nakayama, G ^a   Koike, M ^a   Nakao, A ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastric cancer; Lymphadenectomy; Metastasis

Indexed keywords

EID: 62249171219     PISSN: 00015458     EISSN: 25770160     Source Type: Journal    
DOI: 10.1080/00015458.2009.11680367     Document Type: Review

References (76)

1. KAMANGAR F., DORES G. M., ANDERSON W. F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 2006, 24: 2137-50.
2. VAN CUTSEM E., VAN DE VELDE C., ROTH A. et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal group. Eur J Cancer, 2008, 44: 182-94.
3. MACDONALD J., SMALLEY S., BENEDETTI J. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Eng J Med, 2001, 345: 725-30.
4. CUNNINGHAM D., ALLUM W. H., STENNING S. P. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355: 11-20.
5. CUNNINGHAM D., STARLING N, RAO S. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 2008, 358: 36-46.
6. SAKURAMOTO S., SASAKO M., YAMAGUCHI T. et al. Adjuvant chemotherapy for gastric cancer with S-1, and oral fluoropyrimidine. N Engl J Med, 2007, 357: 1810-20.
7. NAKAJIMA T., KINOSHITA T., NASHIMOTO A. et al. Randomiazed controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg, 2007, 94: 1468-76.
8. KODERA Y., SCHWARZ R. E., NAKAO A. Extended lymph node dissection in gastric carcinoma : Where do we stand after the Dutch and British randomized trials ? J Am Coll Surg, 2002, 195: 855-64.
9. GERVASONI Jr. J. E., SBAYI S., CADY B. Role of lymphadenectomy in surgical treatment of solid tumors: An update on the clinical data. Ann Surg Oncol, 2007, 14: 2443-62.
10. MCNEER G., LAWRENCE W., ORTEGA L. G. et al. Early results of extended total gastrectomy for cancer. Cancer 1956, 9: 1153-1159.
11. JINNAI D. Evaluation of extended radical operation for gastric cancer, with regard to lymph node metastasis and follow-up results. Jpn J Cancer Res 1968, 3: 225-31.
12. nd English Edition. Gastric Cancer 1998, 1: 10-24.
13. DEGIULI M., VENDRAME A., MUZIO S., SASAKO M., MARUYAMA K. The standard D2 gastrectomy for advanced gastric cancer. In: DEGIULI M. eds. Management of gastric cancer: Recent advances. Turin: Minerva Medica, 2008: 177-194.
14. KODERA Y., NAKAO A. Extended surgery (D3) for advanced gastric cancer. In: DEGIULI M. eds. Management of gastric cancer: Recent advances. Turin: Minerva Medica, 2008: 213-222.
15. SIEWERT J. R., BOTTCHER K., STEIN H. J. et al. Relevant prognostic factors in gastric cancer. Ten-year results of the German Gastric Cancer Study. Ann Surg 1998, 228: 449-61.
16. MAEHARA Y., HASUDA S., KOGA T. et al. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg, 2000, 87: 353-7.
17. YOO C. H., NOH S. H., SHIN D.W. et al. Recurrence following curative resection for gastric carcinoma. Br J Surg, 2000, 87: 236-42.
18. SASAKO M., MCCULLOCH P., KINOSHITA T., MARUYAMA K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1995, 82: 346-51.
19. SCARTOZZI M., GALIZIA E., GRAZIANO F. et al. Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. Br J Cancer, 2005, 92: 1051-4.
20. KODERA Y., YAMAMURA Y., TORII A. et al. Postoperative staging of gastric carcinoma. Scand J Gastroenteml 1996, 31: 476-80.
21. ROUKOS D. H., LORENZ M., ENCKE A. Evidence of survival benefit of extended (D2) lymphadenectomy in Western patients with gastric cancer base on a new concept: A prospective long-term follow-up study. Surgery, 1998, 123: 573-578.
22. BOLLSCHWEILER E., BOETTCHER K., HOELSCHER A. H. et al. Is the prognosis for Japanese and German patients with gastric cancel-really different ? Cancer 1993, 71: 2918-25.
23. CUSCHIERI A., WEEDEN S., FIELDING J. et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999, 79: 1522-30.
24. BONENKAMP J. J., HERMANS J., SASAKO M. et al. Extended lymphnode dissection for gastric cancer. N Engl J Med 1999, 340: 908-14.
25. SASAKO M. Risk factors for surgical treatment in the Dutch gastric-cancer trial. Br J Surg 1997, 84, 1567-71.
26. HARTGRINK H. H., VAN DE VELDE C. J., PUTTER H. et al. Extended lymph node dissection for gastric cabcer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol, 2004, 22: 2069-77.
27. MCCULLOCH P., NIITA M. E., KAZI H., GAMA-RODRIGUES J. J. Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br J Surg, 2005, 92: 5-13.
28. WU C. W., HSIUNG C. A., LO S. S. et al. Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol, 2006, 7: 309-15.
29. LEE J. H., RYU K. W., LEE J.-H. et al. Learning curve for total gastrectomy with D2 lymph node dissection: Cumulative sum analysis for qualified surgery. Ann Surg Oncol, 2006, 13: 1175-81.
30. BABA M., HOKITA S., NATSUGOE S. et al. Paraaortic lymphadenectomy in patients with advanced carcinoma of the upper-third of the stomach. Hepatogastroenterol. 2000, 33: 893-896.
31. KUNISAKI C., SHIMADA H., YAMAOKA H. et al. Indication for paraaortic lymph node dissection in gastric cancer patients with paraaortic lymph node involvement. Hepatogastroenterol. 2000, 47: 586-589.
32. ISOZAKI H., OKAJIMA K., FUJII K. et al. Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepatogastroenterol, 1999, 46: 549-54.
33. TAKASHIMA S., KOSAKLA T. Results and controversial issues regarding a para-aortic lymph node dissection for advanced gastric cancer. Surg Today, 2005, 35: 425-31.
34. SANO T., SASAKO M., YAMAMOTO S. et al. Gastric cancer surgery: results of morbidity and mortality of a prospective randomized controlled trial (JCOG9501) comparing D2 and extended paraaortic lymphadenectomy. J Clin Oncol, 2004, 22: 2767-73.
35. SASAKO M., SANO T., YAMAMOTO S. et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med, 2008, 359: 453-62.
36. KODERA Y., SASAKO M., YAMAMOTO S. et al. Identification of risk factors for the development of cimplications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg, 2005, 92: 1103-9.
37. YONEMURA Y., Wu C. C., FUKUSHIMA N. et al. Metastasis in paraaortic lymph nodes in patients with advanced gastric cancer, treated with extended lymphadenectomy. Hepatogastroenterol, 2007, 54: 634-8.
38. KUNISAKI C., AKIYAMA H., NOMURA M. et al. Comparison of surgical results of D2 versus D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric carcinoma: a multi-institutional study. Ann Surg Oncol, 2006, 13: 659-67.
39. KULIG J., POPIELA T., KOLODZIEJCZYK P. et al. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg, 2007, 193: 10-15.
40. NOMURA E., SASAKO M., YAMAMOTO S. et al. Risk factors for paraaortic lymph node metastasis of gastric cancer from a randomized controlled trial of JCOG9501. Jpn J Clin Oncol, 2007, 38: 429-33.
41. JAPAN GASTRIC CANCER ASSOCIATION. Gastric Cancer Treatment Guidelines. Tokyo: Kanehara Shuppan, 2001 (in Japanese: a synopsis in English is available at www.jgca.jp/PDFfiles/).
42. OKINAGA K., IINUMA H., KITAMURA Y. et al. Effect of immunotherapy and spleen preservation on immunological function in patients with gastric cancer. J Exp Clin Cancer Res, 2006, 25: 339-49.
43. WEITZ J., JACQUES D. P., BRENNAN M., KARPEH M. Association of splenectomy with postoperative complications in patients with proximal gastric and gastroesophageal junction cancer. Ann Surg Oncol, 2004, 11: 682-9.
44. KATAI H., YOSHIMURA K., FUKAGAWA T. et al. Risk factors for pancreas-related absecess after total gastrectomy. Gastric Cancer, 2005, 8: 137-41.
45. FATOUROS M., ROUKOS D. H., LORENZ M. et al. Impact of spleen preservation in patients with gastric cancer. Anitcancer Res, 2005, 25: 3023-30.
46. KODERA Y., YAMAMURA Y., SHIMIZU Y. et al. Lack of benefit of combined pancreaticosplenectomy in D2 resection for proximal-third gastric carcinoma. World J Surg 1997, 21: 622-8.
47. KUNISAKI C., MAKING H., SUWA H. et al. Impact of splenectomy in patients with gastric adenocarcinoma of the cardia. J Gastointesti Surg, 2007, 11: 1039-44.
48. ZHANG C. H., ZHANG W. H., HE Y. L. et al. Spleen preservation in radical surgery for gastric cardia cancer. Ann Surg Oncol, 2007, 14: 1312-9.
49. SHEN J. G., CHEONG J. H., HHYUNG W. J. et al. Adverse effect of splenectomy on recurrence in total gastrectomy cancer patients with perioperative transfusion. Am J Surg, 2006, 192: 301-5.
50. LEE K. Y., NOH S. H., HYUNG W. J. et al. Impact of splenectomy for lymph node dissection on long-term surgical outcome in gastric cancer. Ann Surg Oncol, 2002, 8: 402-6.
51. KWON S. J. Prognostic impact of splenectomy on gastric cancer: results of the Korean Gastric Cancer Study Group. World J Surg 1997, 21: 837-44.
52. YAMAMOTO M., BABA H., KAKEJI Y. et al. Postoperative morbidity/mortality and survival rates after total gastrectomy, with splenectomy/pancreaticosplenectomy for patients with advanced gastric cancer. Hepatogastroenterol, 2004, 51: 298-302.
53. YU W., CHOI G. S., CHUNG H. Y. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg, 2006, 93: 559-63.
54. SANO T., YAMAMOTO S., SASAKO M. et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma : Japan Clinical Oncology Group Study JCOG0110-MF. Jpn J Clin Oncol, 2002, 32: 363-364.
55. MARUYAMA K., SASAKO M., KINOSHITA T., SANO T., KATAI H., OKAJIMA K. Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995, 19: 532-6.
56. NOBUOKA D., GOTOHDA N., KONISHI M., NAKAGOHRI T., TAKAHASHI S., KINOSHITA T. Prevention of postoperative pancreatic fistula after total gastrectomy. World J Surg, 2008, 32: 2261-6.
57. SHRIKHANDE S. V., SHUKLA P. L., QURESHI S. et al. D2 lymphadenectomy for gastric cancer in Tata Memorial Hospital: Indian data can now be incorporated in future international trials. Dig Surg, 2006, 23: 192-7.
58. SASAGAWA T., SOLANO H., VEGA W., MENA F. The effectiveness of extended lypm node dissection for gastric cancer performed in Costa Rica under the supervision of a Japanese surgeon: a comparison with surgical results in Japan. Am J Surg, 2008, 195: 53-60.
59. COLLARD J.-M., MALAISE J., MARBUT J.-Y., KESTENS P.-J. Skeletonizing en-bloc gastrectomy for adenocaricnoma in Caucasian patients. Gastric Cancer, 2003, 6: 210-6.
60. SIERRA A., REGUERIA F. M., HERNANDEZ- LIZOAIN J. L. et al. Role of the extended lymphadenectomy in gastric cancer surgery: Experience in a single institution. Ann Surg Oncol, 2003, 10: 219-26.
61. PORTANOVA M., VARGAS F., LOMBARDI E. et al. Results of specialization in the surgical treatment of gastric cancer in Peru. Gastric Cancer, 2007, 10: 92-7.
62. DIAZ DE LIANO A., YARNOZ C., AGUILAR R., ARTIEDA C., ORTIZ H. Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer, 2008, 11: 96-102.
63. EDWARDS P., BLACKSHAW G. R. J. C., LEWIS W. G., BARRY J. D., ALLISON M. C., JONES D. R. B. Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma. Br J Cancer, 2004, 90: 1888-92.
64. BIFFI R., CHIAPPA A., KUCA F. et al. Extended lymph node dissection without routine spleno-pancreatectomy for treatment of gastric cancer : low morbidity and mortality rates in as single center series of 250 patients. J Surg Oncol, 2006, 93: 394-400.
65. DEGIULI M., SASAKO M., CALGARO M. et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer : interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomized surgical trial. Eur J Surg Oncol, 2004, 30: 303-8.
66. HUNDAHL S. A., MACDONALD J. S., BENEDETTI J. et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer : the effect of undertreatment. Ann Surg Oncol, 2002, 9: 278-86.
67. SIEWERT J. R., KELSEN D., MARUYAMA K. et al. Gastric cancer diagnosis and treatment-an interactive training program. New York: Springer Electronic Media, 2000.
68. PEETERS K. C. M. J., HUNDAHL S. A., KRANENBARG E. K., HARTGRINK H., VAN DE VELDE C. J. J. Low Maruyama Index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial. World J Surg, 2005, 29: 1576-84.
69. HUNDAHL S. A., PEETERS K. C. M. J., KRANENBARG E. K., HARTGRINK H., VAN DE VELDE C. J. H. Improved regional control and survival with "low Maruyama Index" surgery in gastric cancer : autopsy findings from the Dutch D1-D2 trial. Gastric Cancer, 2007, 10: 84-86.
70. SMITH D. D., SCHWARZ R. R., SCHWARZ R. E. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer : Data from a large US-population database. J Clin Oncol, 2005, 28: 7114-24.
71. KATTAN N. W., KARPEH M.S., MAZUMDAR M., BRENNAN M. F. Postoperative notnogram for disease-specific survival after an RO resection for gastric carcinoma. J Clin Oncol, 2003, 21: 3647-50.
72. PEETERS K. C., KATTAN M. W., HARTGRINK H. H., KRANENBARG E. K., KARPEH M. S., BRENNAN M. F., VAN DE VELDE C. J. Validation of a nomogram for predicting disease-specific survival after an RO resection for gastric carcinoma. Cancer, 2005, 103: 702-7.
73. NOVOTONY A. R., SCHUHMACHER C., BUSCH R., KATTAN M. W., BRENNAN M. F., SIEWERT J. R. Predicting individual survival after gastric cancer resection : validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg, 2006, 243: 74-81.
74. AJANI J. A. Operate on my stomach cancer? Oh, no-Not you, or not yet ! J Clin Oncol, 2004, 22: 1763-4.
75. SCHWARZ R. E., SMITH D. D. Extended lymph node dissection for gastric cancer: Who may benefit ? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol, 2005, 23: 5404.
76. PRAMESH C. S., KULKARNI N. N., MISTRY R. C., BADWE R. A. Lymphadenectomy in cancer : time for a paradigm shift ? Lancet Onol, 2006, 7: 450-1.